INTEGRITY AGREEMENT
BETWEEN THE
OFFICE OF INSPECTOR GENERAL
OF THE
DEPARTMENT OF HEALTH AND HUMAN SERVICES
AND
SOLERA SPECIALTY PHARMACY, LLC
AND NICHOLAS SARANITI

I. PREAMBLE

Solera Specialty Pharmacy, LLC (SSP) and Nicholas Saraniti (Saraniti) (SSP and Saraniti are referred to collectively as “Solera”) hereby enter into this Integrity Agreement (IA) with the Office of Inspector General (OIG) of the United States Department of Health and Human Services (HHS) to promote compliance with the statutes, regulations, and written directives of Medicare, Medicaid, and all other Federal health care programs (as defined in 42 U.S.C. § 1320a-7b(f)) (Federal health care program requirements). Contemporaneously with this IA, Solera Specialty Pharmacy, LLC and Nicholas Saraniti are entering into a Settlement Agreement with the United States.

II. TERM AND SCOPE OF THE IA

A. The Effective Date of this IA shall be the date on which the final signatory signs this IA. The term of this IA shall be three years from the Effective Date. Each one-year period, beginning with the one-year period following the Effective Date, shall be referred to as a “Reporting Period.”

B. Sections VII, X, and XI shall expire no later than 120 days after OIG’s receipt of: (1) Solera’s final annual report; or (2) any additional materials submitted by Solera pursuant to OIG’s request, whichever is later.

C. The term “Covered Persons” includes: (1) all owners (including Saraniti) and employees of SSP; and (b) all contractors, agents, and other persons who furnish patient care items or services or who perform billing or coding functions on behalf of Solera, except that the employees of any third party billing company that submits claims to the Federal health care programs on behalf of Solera shall not be considered Covered Persons, provided that Solera and the third party billing company provide the certifications required by Section III.J.
D. The term “prior authorization” or “PA” includes: documentation that a payor requires a prescriber to complete prior to covering the medication. Prior authorization includes, but is not limited to: pre-authorization, prior approval, predetermination, and non-formulary exception requests.

III. COMPLIANCE PROGRAM REQUIREMENTS

Solera shall establish and maintain a compliance program that includes the following elements:

A. Compliance Contact

Within 90 days after the Effective Date, Solera shall designate a Compliance Contact and shall maintain a Compliance Contact for the term of the IA. The Compliance Contact shall be responsible for: (1) monitoring Solera’s day-to-day compliance activities, (2) meeting any reporting requirements created under this IA, and (3) responding to questions and concerns from OIG regarding Solera’s compliance with the IA. The Compliance Contact shall make periodic (at least quarterly) reports regarding compliance matters to the Chief Executive Officer of Solera. Written documentation of the Compliance Contact’s reports to the Chief Executive Officer shall be made available to OIG upon request. The Compliance Contact shall not have any responsibilities that involve acting in any capacity as legal counsel or supervising legal functions for Solera and any non-compliance job responsibilities shall not involve billing, coding, or claim submission (or oversight for those functions) for Solera.

Solera shall report to OIG, in writing, any changes in the identity or job responsibilities of the Compliance Contact, or any actions or changes that would affect the Compliance Contact’s ability to perform the duties necessary to meet the requirements in this IA, within five business days after such a change.

B. Policies and Procedures

Within 90 days after the Effective Date, Solera shall develop and implement written policies and procedures for compliance with Federal health care program requirements regarding (1) the handling and dispensing of prescription drugs, (2) maintaining appropriate documentation of prescriptions for all prescription drugs dispensed (including refills), (3) obtaining prior authorizations when required by the payor, and (4) the collection and waiver of cost-sharing amounts (Policies and Procedures). Throughout the term of this IA, Solera shall enforce its Policies and Procedures and shall make such compliance an element of evaluating the performance of all employees.

Solera Specialty Pharmacy and Nicholas Saraniti IA
The Policies and Procedures shall be made available to all Covered Persons.

At least annually (and more frequently, if appropriate), Solera shall assess and update, as necessary, the Policies and Procedures. Any revised or new Policies and Procedures shall be made available to all Covered Persons. All Policies and Procedures shall be made available to OIG upon request.

C. Posting of Notice

Within 90 days after the Effective Date, Solera shall post in a prominent place accessible to all patients and Covered Persons a notice that provides the name and phone number of the Compliance Contact and the HHS OIG Fraud Hotline telephone number (1-800-HHS-TIPS) as a confidential means by which suspected fraud or abuse in the Federal health care programs may be reported. Solera shall also post the same notice on its website.

D. Training and Education

1. Covered Persons Training. All Covered Persons shall receive at least three hours of training during the first Reporting Period. Any individuals who become Covered Persons after the Effective Date and during the term of this IA shall receive at least three hours of training within 90 days of becoming a Covered Person.

Training may be completed in-person or online. These training requirements may be satisfied only by the completion of training courses that are submitted to OIG, prior to registration for the training course, for review and approval.

At a minimum, the required training sessions must include the following topics:

a. the Federal health care program statutes, regulations, and program requirements and directives relating to the handling, dispensing and claims submission for prescription drugs furnished by Solera;

b. the Federal health care program and applicable state Board of Pharmacy requirements relating to the documentation of prescriptions for prescription drugs dispensed (including any refills) by Solera;
c. the personal obligation of each individual involved in the claims submission processes to ensure that prescription documentation and claims are accurate; and

d. the requirements of 42 U.S.C. § 1320a-7b(b) (the Anti-Kickback Statute) and 42 U.S.C. § 1395nn (the Stark Law), the legal sanctions under the Anti-Kickback Statute and the Stark Law, and examples of violations of the Anti-Kickback Statute and Stark Law.

The OIG may, in its discretion, require that all Covered Persons complete additional hours of training regarding the topics identified above, or additional topics, in the second or third years of the IA. The OIG shall provide notice to Solera of such additional required training at least 180 days prior to the required completion date for such training.

2. Training Records. Solera shall maintain written documentation (e.g., written or electronic certificates of completion from the training provider) that all Covered Persons required to receive training have in fact completed such training. The documentation shall specify the type of training received, the individual who completed the training, and the date received.

E. Review Procedures

1. General Description.

a. Engagement of Independent Review Organization. Within 90 days after the Effective Date, Solera shall engage an individual or entity, such as an accounting, auditing, or consulting firm (hereinafter “Independent Review Organization” or “IRO”), to perform the reviews listed in this Section III.E. The applicable requirements relating to the IRO are outlined in Appendix A to this IA, which is incorporated by reference.

b. Retention of Records. The IRO and Solera shall retain and make available to OIG, upon request, all work papers, supporting documentation, correspondence, and draft reports (those exchanged between the IRO and Solera) related to the reviews.
c. **Access to Records and Personnel.** Solera shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in this Section III.E and that all records furnished to the IRO are accurate and complete.

2. **Claims Review.** The IRO shall conduct a review of Solera’s claims submitted to and reimbursed by the Medicare and Medicaid programs for each three-month period during the term of this IA (Quarterly Claims Review) and shall prepare a Quarterly Claims Review Report, as outlined in Appendix B to this IA, which is incorporated by reference. Each Quarterly Claims Review shall include findings regarding whether: (1) the prescription drugs furnished by Solera were dispensed according to a valid prescription, (2) Solera maintained appropriate documentation of a valid prescription for each prescription drug dispensed (including any prescription refills), (3) any prior authorization required by the payor was obtained in accordance with the payor’s requirements, (4) all cost-sharing amounts were collected or waived in accordance with applicable payor requirements, and (5) all claims were appropriately submitted and reimbursed. The first three-month period for purposes of the Quarterly Claims Review requirement shall begin 30 days after the Effective Date. Each Quarterly Claims Review Report shall be submitted to OIG within 60 days following the end of the three-month period covered by the Quarterly Claims Review.

3. **Independence and Objectivity Certification.** Prior to performing the first Quarterly Claims Review, and annually thereafter, the IRO shall submit to Solera a certification that the IRO has (a) evaluated its professional independence and objectivity with respect to the reviews required under this Section III.E and (b) concluded that it is, in fact, independent and objective, in accordance with the requirements specified in Appendix A to this IA. The IRO’s certification shall include a summary of all current and prior engagements between Solera and the IRO.

F. **Ineligible Persons**

1. **Definitions.** For purposes of this IA:

   a. an “Ineligible Person” shall include an individual or entity who:

      i. is currently excluded from participation in any Federal health care program; or

      ii. has been convicted of (a) a criminal offense that is related to the delivery of an item or service under
Medicare or any state health care program; (b) a
criminal offense relating to neglect or abuse of
patients; (c) a felony criminal offense relating to fraud,
theft, embezzlement, breach of fiduciary
responsibility, or other financial misconduct in
connection with the delivery of a health care item or
service or with respect to a government funded health
care program (other than Medicare or a state health
care program); or (d) a felony criminal offense relating
to the unlawful manufacture, distribution, prescription
or dispensing of a controlled substance, but has not yet
been excluded, debarred, suspended, or otherwise
declared ineligible.

b. “Exclusion List” means the HHS/OIG List of Excluded
Individuals/Entities (LEIE) (available through the Internet at

2. Screening Requirements. Solera shall ensure that all prospective and
current Covered Persons are not Ineligible Persons, by implementing the following
screening requirements.

a. Solera shall screen all prospective Covered Persons against
the Exclusion List prior to engaging their services and, as part
of the hiring or contracting process, shall require such
Covered Persons to disclose whether they are Ineligible
Persons.

b. Solera shall screen all current Covered Persons against the
Exclusion List within 30 days after the Effective Date and on
a monthly basis thereafter.

c. Solera shall require all Covered Persons to immediately
disclose immediately if they become an Ineligible Person.

Solera shall maintain documentation in order to demonstrate that Solera: (1) has
checked the Exclusion List (i.e., a print screen of the search results) and determined that
its Covered Persons are not Ineligible Persons; and (2) has required its Covered Persons
to disclose if they are an Ineligible Person.
Nothing in this Section III.F affects Solera’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. Solera understands that items or services furnished by excluded persons are not payable by Federal health care programs and that Solera may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether Solera meets the requirements of Section III.F.

3. **Removal Requirement.** If Solera has actual notice that a Covered Person has become an Ineligible Person, Solera shall remove such Covered Person from responsibility for, or involvement with, Solera’s business operations related to the Federal health care program(s) from which such Covered Person has been excluded and shall remove such Covered Person from any position for which the Covered Person’s compensation or the items or services furnished, ordered, or prescribed by the Covered Person are paid in whole or part, directly or indirectly, by any Federal health care program(s) from which the Covered Person has been excluded at least until such time as the Covered Person is reinstated into participation in such Federal health care program(s).

4. **Pending Charges and Proposed Exclusions.** If Solera has actual notice that a Covered Person is charged with a criminal offense that falls within the scope of 42 U.S.C. §§ 1320a-7(a), 1320a-7(b)(1)-(3), or is proposed for exclusion during the Covered Person’s employment or contract term, Solera shall take all appropriate actions to ensure that the responsibilities of that Covered Person have not and shall not adversely affect the quality of care rendered to any beneficiary or the accuracy of any claims submitted to any Federal health care program.

G. **Notification of Government Investigation or Legal Proceeding**

Within 30 days after discovery, Solera shall notify OIG, in writing, of any ongoing investigation or legal proceeding known to Solera conducted or brought by a governmental entity or its agents involving an allegation that Solera has committed a crime or has engaged in fraudulent activities. This notification shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding. Solera shall also provide written notice to OIG within 30 days after the resolution of the matter and shall provide OIG with a description of the findings and/or results of the investigation or proceeding, if any.

H. **Overpayments**
1. **Definition of Overpayments.** An “Overpayment” means any funds that Solera receives or retains under any Federal health care program to which Solera, after applicable reconciliation, is not entitled under such Federal health care program.

2. **Overpayment Policies and Procedures.** Within 90 days after the Effective Date, Solera shall develop and implement written policies and procedures regarding the identification, quantification and repayment of Overpayments received from any Federal health care program.

3. **Repayment of Overpayments.** If, at any time, Solera identifies any Overpayment, Solera shall repay the Overpayment to the appropriate payor (e.g., Medicare contractor) in accordance with the requirements of 42 U.S.C. § 1320a-7k(d) and any applicable regulations and guidance from the Centers for Medicare and Medicaid Services (CMS). Solera should follow the payor’s policies regarding the form of notification and the repayment process for any Overpayment refunds. Any questions regarding the repayment process should be directed to the payor.

I. **Reportable Events**

1. **Definition of Reportable Event.** For purposes of this IA, a “Reportable Event” means anything that involves:

   a. a substantial Overpayment;

   b. a matter that a reasonable person would consider a probable violation of criminal, civil, or administrative laws applicable to any Federal health care program for which penalties or exclusion may be authorized;

   c. the employment of or contracting with a Covered Person who is an Ineligible Person as defined by Section III.F.1.a; or

   d. the filing of a bankruptcy petition by Solera.

A Reportable Event may be the result of an isolated event or a series of occurrences.

2. **Reporting of Reportable Events.** If Solera determines (after a reasonable opportunity to conduct an appropriate review or investigation of the allegations) through any means that there is a Reportable Event, Solera shall notify OIG, in writing, within 30 days after making the determination that the Reportable Event exists.
3. **Reportable Events under Section III.I.1.a. and III.I.1.b.** For Reportable Events under Section III.I.1.a and b, the report to OIG shall include:

a. a complete description of all details relevant to the Reportable Event, including, at a minimum, the types of claims, transactions or other conduct giving rise to the Reportable Event; the period during which the conduct occurred; and the names of entities and individuals believed to be implicated, including an explanation of their roles in the Reportable Event;

b. a statement of the Federal criminal, civil or administrative laws that are probably violated by the Reportable Event, if any;

c. the Federal health care programs affected by the Reportable Event;

d. a description of the steps taken by Solera to identify and quantify any Overpayments; and

e. a description of Solera’s actions taken to correct the Reportable Event and prevent it from recurring.

If the Reportable Event involves an Overpayment, within 60 days of identification of the Overpayment, Solera shall repay the Overpayment, in accordance with the requirements of 42 U.S.C. §1320a-7k(d) and any applicable regulations and Centers for Medicare and Medicaid Services (CMS) guidance and provide OIG with a copy of the notification and repayment.

4. **Reportable Events under Section III.I.1.c.** For Reportable Events under Section III.I.1.c, the report to OIG shall include:

a. the identity of the Ineligible Person and the job duties performed by that individual;

b. the dates of the Ineligible Person’s employment or contractual relationship;

c. a description of the Exclusion List screening that Solera
completed before and/or during the Ineligible Person’s employment or contract and any flaw or breakdown in the screening process that led to the hiring or contracting with the Ineligible Person;

d. a description of how the Ineligible Person was identified; and

e. a description of any corrective action implemented to prevent future employment or contracting with an Ineligible Person.

5. Reportable Events under Section III.I.1.d. If the Reportable Event involves the filing of a bankruptcy petition, the report to the OIG shall include documentation of the bankruptcy filing and a description of any Federal health care program requirements implicated.

6. Reportable Events Involving the Stark Law. Notwithstanding the reporting requirements outlined above, any Reportable Event that involves solely a probable violation of section 1877 of the Social Security Act, 42 U.S.C. §1395nn (the Stark Law) should be submitted by Solera to CMS through the self-referral disclosure protocol (SRDP), with a copy to the OIG. If Solera identifies a probable violation of the Stark Law and repays the applicable Overpayment directly to the CMS contractor, then Solera is not required by this Section III.I to submit the Reportable Event to CMS through the SRDP.

J. Third Party Billing

If, prior to the Effective Date or at any time during the term of this IA Solera contracts with a third party billing company to submit claims to the Federal health care programs on behalf of Solera, Solera must certify to OIG that it does not have an ownership or control interest (as defined in 42 U.S.C. § 1320a-3(a)(3)) in the third party billing company.

Solera also shall obtain (as applicable) a certification from any third party billing company that the company: (1) has a policy of not employing any person who is excluded from participation in any Federal health care program to perform any duties related directly or indirectly to the preparation or submission of claims to Federal health care programs; (2) screens its prospective and current employees against the Exclusion List; and (3) provides training in the applicable requirements of the Federal health care programs to those employees involved in the preparation and submission of claims to Federal health care programs.
If applicable, a copy of these certifications shall be included in Solera’s Implementation Report and each Annual Report required by Section V below.

IV. SUCCESSOR LIABILITY; CHANGES TO LOCATIONS OR BUSINESS; NEW EMPLOYMENT OR CONTRACTUAL ARRANGEMENT

In the event that, after the Effective Date, SSP or Saraniti proposes to (a) sell any or all of its locations or businesses that are subject to this IA (whether through a sale of assets, sale of stock, or other type of transaction), or (b) purchase or establish a new location or business related to the furnishing of items or services that may be reimbursed by any Federal health care program, the IA shall be binding on the purchaser of any such location or business and any new location or business (and all Covered Persons at each new location or business) shall be subject to the requirements of this IA, unless otherwise determined and agreed to in writing by OIG. SSP or Saraniti (as applicable) shall give notice of such sale or purchase to OIG within 30 days following the closing of the transaction.

If, in advance of a proposed sale or proposed purchase, SSP or Saraniti wishes to obtain a determination by OIG that the proposed purchaser or the proposed acquisition will not be subject to the requirements of the IA, SSP or Saraniti (as applicable) must notify OIG in writing of the proposed sale or purchase at least 30 days in advance. This notification shall include a description of the location or business to be sold or purchased, a brief description of the terms of the transaction and, in the case of a proposed sale, the name and contact information of the prospective purchaser.

At least 30 days prior to Saraniti becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by any Federal health care program, Saraniti shall notify OIG of his plan to become an employee or contractor and must provide OIG with the name, location, status (employee or contractor) and an explanation of Saraniti’s responsibilities with respect to such potential employer or contractor. In addition, prior to Saraniti becoming an employee or contractor with another party related to the furnishing of items or services that may be reimbursed by any Federal health care program, Saraniti shall notify that party of this IA. This notification shall include a copy of the IA and a statement indicating the remaining term of the IA. The IA shall continue to apply to Saraniti following the start of the new employment or contractual relationship, unless otherwise agreed to in writing by the OIG.

V. IMPLEMENTATION REPORT, IRO REPORTS, AND ANNUAL REPORTS

A. Implementation Report

Solera Specialty Pharmacy and Nicholas Saraniti IA
Within 90 days after the Effective Date, Solera shall submit a written report to OIG summarizing the status of its implementation of the requirements of this IA (Implementation Report). The Implementation Report shall, at a minimum, include:

1. the name, address, phone number, and position description of the Compliance Contact required by Section III.A, and a summary of other noncompliance job responsibilities the Compliance Contact may have;

2. a list of the Policies and Procedures required by Section III.B.;

3. a copy of the notice required by Section III.C, a description of where the notice is posted, and the date the notice was posted;

4. the following information regarding the IRO: (a) identity, address, and phone number; (b) a copy of the engagement letter; (c) information to demonstrate that the IRO has the qualifications outlined in Appendix A to this IA; and (d) a certification from the IRO regarding its professional independence and objectivity with respect to Solera that includes a summary of all current and prior engagements between Solera and the IRO;

5. a copy of the search result print screens demonstrating that Solera has screened all Covered Persons against the Exclusion List as required by Section III.F within 30 days of the Effective Date;

6. a copy of Solera’s policies and procedures regarding the identification, quantification and repayment of Overpayments required by Section III.H;

7. a copy of any certifications from Solera and the third party billing company required by Section III.J (if applicable);

8. a list of all of Solera’s locations (including locations and mailing addresses), the corresponding name under which each location is doing business, and each location’s Medicare and state Medicaid program provider number(s), and/or supplier number(s); and

9. a certification by Saraniti in his individual capacity, SSP’s Compliance Contact, and SSP’s Chief Executive Officer that: (a) he or she has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his or her knowledge, except as otherwise described in the Implementation Report, Solera is in compliance with all of the requirements of this...
IA; (c) he or she has reviewed the Implementation Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful; and (d) he or she understands that this certification is being provided to and relied upon by the United States.

B. **IRO Reports**

Within 60 days following the end of each three-month period during the term of this IA, Solera shall provide to OIG a copy of the Quarterly Claims Review Report prepared by the IRO for each Quarterly Claims Review performed, along with Solera’s response and corrective action plan related to any recommendations made by the IRO in the Quarterly Claims Review Report. Each Quarterly Claims Review Report shall include the information specified in Appendix B to this IA.

C. **Annual Reports**

Solera shall submit to OIG a report on its compliance with the IA requirements for each of the three Reporting Periods (Annual Report). Each Annual Report shall include, at a minimum, the following information:

1. any change in the identity, position description, or other noncompliance job responsibilities of the Compliance Contact described in Section III.A;

2. a list of any new or revised Policies and Procedures developed during the Reporting Period;

3. (in the first Annual Report) the following information regarding the training required by Section III.D: a copy of the training program registration for each Covered Person who completed the training, the name of the training course, the name of the entity that provided the training, the location, date and length of the training; and a training program brochure or other materials from the training program or training program sponsor that describes the content of the training program. A copy of all training materials shall be made available to OIG upon request;

4. a certification from the IRO regarding its professional independence and objectivity with respect to Solera that includes a summary of all current and prior engagements between Solera and the IRO;

5. a copy of the search result print screens demonstrating that Solera screened all prospective and current Covered Persons against the Exclusion List, as required by Section III.F;

*Solera Specialty Pharmacy and Nicholas Saraniti IA*
6. a summary describing any ongoing investigation or legal proceeding required to have been reported pursuant to Section III.G. The summary shall include a description of the allegation, the identity of the investigating or prosecuting agency, and the status of such investigation or legal proceeding;

7. a description of any changes to the Overpayment policies and procedures required by Section III.H, including the reasons for such changes;

8. a report of the aggregate Overpayments that have been returned to the Federal health care programs during the Reporting Period. Overpayment amounts shall be broken down into the following categories: Medicare, Medicaid, and other Federal health care programs;

9. a summary of Reportable Events (as defined in Section III.I) identified during the Reporting Period;

10. a copy of any certifications from Solera and the third party billing company required by Section III.J (if applicable);

11. a summary of any audits conducted during the applicable Reporting Period by any Medicare or state Medicaid program contractor or any government entity or contractor, involving a review of Federal health care program claims, and Solera’s response/corrective action plan (including information regarding any Federal health care program refunds) relating to the audit findings;

12. a description of all changes to the most recently provided list of Solera’s locations (including addresses) as required by Section V.A.8; and

13. certification by Saraniti in his individual capacity, SSP’s Compliance Contact, and SSP’s Chief Executive Officer that: (a) he or she has reviewed the IA in its entirety, understands the requirements described within, and maintains a copy for reference; (b) to the best of his or her knowledge, except as otherwise described in the Annual Report, Solera is in compliance with all of the requirements of this IA; (c) he or she has reviewed the Annual Report and has made a reasonable inquiry regarding its content and believes that the information is accurate and truthful; and (d) he or she understands that this certification is being provided to and relied upon by the United States.

Solera Specialty Pharmacy and Nicholas Saraniti IA
The first Annual Report shall be received by OIG no later than 60 days after the end of the first Reporting Period. Subsequent Annual Reports shall be received by OIG no later than the anniversary date of the due date of the first Annual Report.

D. Designation of Information

Solera shall clearly identify any portions of its submissions that it believes are trade secrets, or information that is commercial or financial and privileged or confidential, and therefore potentially exempt from disclosure under the Freedom of Information Act (FOIA), 5 U.S.C. § 552. Solera shall refrain from identifying any information as exempt from disclosure if that information does not meet the criteria for exemption from disclosure under FOIA.

VI. NOTIFICATIONS AND SUBMISSION OF REPORTS

Unless otherwise stated in writing after the Effective Date, all notifications and reports required under this IA shall be submitted to the following entities:

OIG:

Administrative and Civil Remedies Branch
Office of Counsel to the Inspector General
Office of Inspector General
U.S. Department of Health and Human Services
Cohen Building, Room 5527
330 Independence Avenue, SW
Washington, DC 20201
Telephone: (202) 619-2078
Facsimile: (202) 205-0604

Solera:

Richard Dougherty
2100 Park Central Blvd N, Suite 300
Pompano Beach, FL 33064
Telephone: (954) 615-1840
Facsimile: (877) 712-7866

Unless otherwise specified, all notifications and reports required by this IA may be made by electronic mail, overnight mail, hand delivery, or other means, provided that there is proof that such notification was received. Upon request by OIG, Solera may be
required to provide OIG with an additional copy of each notification or report required by this IA in OIG’s requested format (electronic or paper).

VII. OIG INSPECTION, AUDIT, AND REVIEW RIGHTS

In addition to any other rights OIG may have by statute, regulation, or contract, OIG or its duly authorized representative(s) may conduct interviews, examine and/or request copies of Solera’s books, records, and other documents and supporting materials and conduct on-site reviews of any of Solera’s locations, for the purpose of verifying and evaluating: (a) Solera’s compliance with the terms of this IA and (b) Solera’s compliance with the requirements of the Federal health care programs. The documentation described above shall be made available by Solera to OIG or its duly authorized representative(s) at all reasonable times for inspection, audit, and/or reproduction. Furthermore, for purposes of this provision, OIG or its duly authorized representative(s) may interview any of Solera’s owners, employees, and contractors who consent to be interviewed at the individual’s place of business during normal business hours or at such other place and time as may be mutually agreed upon between the individual and OIG. Solera shall assist OIG or its duly authorized representative(s) in contacting and arranging interviews with such individuals upon OIG’s request. Solera’s owners, employees, and contractors may elect to be interviewed with or without a representative of Solera present.

VIII. DOCUMENT AND RECORD RETENTION

Solera shall maintain for inspection all documents and records relating to reimbursement from the Federal health care programs and to compliance with this IA for four years (or longer if otherwise required by law) from the Effective Date.

IX. DISCLOSURES

Consistent with HHS’s FOIA procedures, set forth in 45 C.F.R. Part 5, OIG shall make a reasonable effort to notify Solera prior to any release by OIG of information submitted by Solera pursuant to its requirements under this IA and identified upon submission by Solera as trade secrets, or information that is commercial or financial and privileged or confidential, under the FOIA rules. With respect to such releases, Solera shall have the rights set forth at 45 C.F.R. § 5.42(a).

X. BREACH AND DEFAULT PROVISIONS

A. Stipulated Penalties

OIG may assess:

Solera Specialty Pharmacy and Nicholas Saraniti IA
1. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.A;

2. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.B;

3. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.C;

4. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.D;

5. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.E;

6. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.F;

7. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.G;

8. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.H;

9. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.I;

10. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section III.J (if applicable);

11. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section IV;

12. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section V;

13. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section VII;
14. A Stipulated Penalty of up to $1,000 for each day Solera fails to comply with Section VIII; or

15. A Stipulated Penalty of up to $50,000 for each false certification or false statement made to OIG by or on behalf of Solera under this IA.

B. Timely Written Requests for Extensions

Solera may, in advance of the due date, submit a timely written request for an extension of time to perform any act or file any notification or report required by this IA. If OIG grants the timely written request with respect to an act, notification, or report, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until one day after Solera fails to meet the revised deadline set by OIG. If OIG denies such a timely written request, Stipulated Penalties for failure to perform the act or file the notification or report shall not begin to accrue until three business days after Solera receives OIG’s written denial of such request or the original due date, whichever is later. A “timely written request” is defined as a request in writing received by OIG at least five business days prior to the date by which any act is due to be performed or any notification or report is due to be filed.

C. Payment of Stipulated Penalties

1. Demand Letter. If OIG determines that a basis for Stipulated Penalties under Section X.A exists, OIG shall notify Solera of: (a) Solera’s failure to comply; and (b) OIG’s demand for payment of Stipulated Penalties. (This notification shall be referred to as the “Demand Letter.”)

2. Response to Demand Letter. Within 15 business days after the date of the Demand Letter, Solera shall either: (a) pay the applicable Stipulated Penalties; or (b) request a hearing before an HHS administrative law judge (ALJ) to dispute OIG’s determination of noncompliance, pursuant to the agreed upon provisions set forth below in Section X.E.

3. Form of Payment. Payment of the Stipulated Penalties shall be made by electronic funds transfer to an account specified by OIG in the Demand Letter.

D. Exclusion for Material Breach of this IA

1. Definition of Material Breach. A material breach of this IA means:
2. **Notice of Material Breach and Intent to Exclude.** The parties agree that a material breach of this IA by Solera constitutes an independent basis for Solera’s exclusion from participation in the Federal health care programs. The length of the exclusion shall be in the OIG’s discretion, but not more than three years for each material breach. Upon a preliminary determination by OIG that Solera has materially breached this IA, OIG shall notify Solera of: (a) Solera’s material breach; and (b) OIG’s intent to exclude Solera. (This notification shall be referred to as the “Notice of Material Breach and Intent to Exclude.”)

3. **Response to Notice.** Solera shall have 30 days from the date of the Notice of Material Breach and Intent to Exclude to submit any information and documentation for OIG to consider before it makes a final determination regarding exclusion.

4. **Exclusion Letter.** If OIG determines that exclusion is warranted, OIG shall notify Solera in writing of its determination to exclude Solera. (This letter shall be referred to as the “Exclusion Letter.”) Subject to the Dispute Resolution
provisions in Section X.E, below, the exclusion shall go into effect 30 days after the date of the Exclusion Letter. The exclusion shall have national effect. The effect of the exclusion shall be that no Federal health care program payment may be made for any items or services furnished, ordered, or prescribed by Solera, including administrative and management services, except as stated in regulations found at 42 C.F.R. 1001.1901(c). Reinstatement to program participation is not automatic. At the end of the period of exclusion, Solera may apply for reinstatement, by submitting a written request for reinstatement in accordance with the provisions at 42 C.F.R. §§ 1001.3001-.3004.

E. Dispute Resolution

1. Review Rights. Upon OIG’s issuing a Demand Letter or Exclusion Letter, and as an agreed-upon remedy for the resolution of disputes arising under this IA, Solera shall be afforded certain review rights comparable to the ones that are provided in 42 U.S.C. § 1320a-7(f) and 42 C.F.R. Part 1005. Specifically, OIG’s determination to demand payment of Stipulated Penalties or to seek exclusion shall be subject to review by an HHS ALJ and, in the event of an appeal, the DAB, in a manner consistent with the provisions in 42 C.F.R. § 1005.2-1005.21, but only to the extent this IA does not provide otherwise. Notwithstanding the language in 42 C.F.R. § 1005: (a) the request for a hearing involving Stipulated Penalties shall be made within 15 days after the date of the Demand Letter and the request for a hearing involving exclusion shall be made within 25 days after the date of the Exclusion Letter; and (b) no discovery shall be available to the parties. The procedures relating to the filing of a request for a hearing can be found at http://www.hhs.gov/dab/divisions/civil/procedures/divisionprocedures.html.

2. Stipulated Penalties Review. Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for Stipulated Penalties under this IA shall be: (a) whether Solera was in full and timely compliance with the requirements of this IA for which OIG demands payment; and (b) the period of noncompliance. Solera shall have the burden of proving its full and timely compliance. If the ALJ upholds the OIG’s determination that Solera has breached this IA and orders Solera to pay Stipulated Penalties, Solera must (a) come into compliance with the requirement(s) that resulted in the OIG imposing Stipulated Penalties and (b) pay the Stipulated Penalties within 20 days after the ALJ issues a decision, unless Solera properly and timely requests review of the ALJ decision by the DAB. If the ALJ decision is properly and timely appealed to the DAB and the DAB upholds the determination of OIG, Solera must (a) come into compliance with the requirement(s) that resulted in the OIG imposing Stipulated Penalties and (b) pay the Stipulated Penalties within 20 days after the DAB issues its decision.
3. **Exclusion Review.** Notwithstanding any provision of Title 42 of the United States Code or Title 42 of the Code of Federal Regulations, the only issues in a proceeding for exclusion based on a material breach of this IA shall be whether Solera was in material breach of this IA. If the ALJ sustains the OIG’s determination of material breach, the exclusion shall take effect 20 days after the ALJ issues the decision. If the DAB finds in favor of OIG after an ALJ decision adverse to OIG, the exclusion shall take effect 20 days after the DAB decision. Solera shall waive its right to any notice by OIG of the exclusion if a decision upholding the exclusion is rendered by the ALJ or DAB. If the DAB finds in favor of Solera, Solera shall be reinstated effective on the date of the exclusion.

4. **Finality of Decision.** The review by an ALJ or DAB provided for above shall not be considered to be an appeal right arising under any statutes or regulations. The parties to this IA agree that the DAB’s decision (or the ALJ’s decision if not appealed) shall be considered final for all purposes under this IA and Solera agrees not to seek additional review of the DAB’s decision (or the ALJ’s decision if not appealed) in any judicial forum.

XI. **EFFECTIVE AND BINDING AGREEMENT**

Solera and OIG agree as follows:

A. This IA shall become final and binding on the date the final signature is obtained on the IA.

B. This IA constitutes the complete agreement between the parties and may not be amended except by written consent of the parties to this IA.

C. OIG may agree to a suspension of Solera’s requirements under this IA based on a certification by Solera that it is no longer providing health care items or services that will be billed to any Federal health care program and it does not have any ownership or control interest, as defined in 42 U.S.C. § 1320a-3, in any entity that bills any Federal health care program. If Solera is relieved of its IA requirements, Solera shall be required to notify OIG in writing at least 30 days in advance if Solera plans to resume providing health care items or services that are billed to any Federal health care program or to obtain an ownership or control interest in any entity that bills any Federal health care program. At such time, OIG shall evaluate whether the IA will be reactivated or modified.

D. All requirements and remedies set forth in this IA are in addition to and do not affect (1) Solera’s responsibility to follow all applicable Federal health care program
requirements or (2) the government’s right to impose appropriate remedies for failure to follow applicable Federal health care program requirements.

E. The undersigned Solera signatories represent and warrant that they are authorized to execute this IA. The undersigned OIG signatories represent that they are signing this IA in their official capacity and that they are authorized to execute this IA.

F. This IA may be executed in counterparts, each of which constitutes an original and all of which constitute one and the same IA. Electronically-transmitted copies of signatures shall constitute acceptable, binding signatures for purposes of this IA.
ON BEHALF OF SSP

/Nicholas Saraniti/ 6/29/2022
NICHOLAS SARANITI
Chief Executive Officer, SSP

/Anthony Mahajan/ 7/6/22
ANTHONY MAHAJAN
Counsel for SSP
Frier Levitt

ON BEHALF OF NICHOLAS SARANITI

/Nicholas Saraniti/ 6/29/2022
NICHOLAS SARANITI
For himself

/Anthony Mahajan/ 7/6/22
ANTHONY MAHAJAN
Counsel for Nicholas Saraniti
Frier Levitt
ON BEHALF OF THE OFFICE OF INSPECTOR GENERAL OF
THE DEPARTMENT OF HEALTH AND HUMAN SERVICES

/Lisa M. Re/ 06/13/2022
LISA M. RE
Assistant Inspector General for Legal Affairs
Office of Inspector General
U. S. Department of Health and Human Services

/Madeline Bainer/ 7/8/2022
MADELINE BAINER
Senior Counsel
Office of Inspector General
U. S. Department of Health and Human Services

Solera Specialty Pharmacy and Nicholas Saraniti IA
APPENDIX A

INDEPENDENT REVIEW ORGANIZATION

This Appendix contains the requirements relating to the Independent Review Organization (IRO) required by Section III.E of the IA.

A. IRO Engagement

1. Solera shall engage an IRO that possesses the qualifications set forth in Paragraph B, below, to perform the responsibilities in Paragraph C, below. The IRO shall conduct the review in a professionally independent and objective fashion, as set forth in Paragraph E. Within 30 days after OIG receives the information identified in Section V.A.4 of the IA or any additional information submitted by Solera in response to a request by OIG, whichever is later, OIG will notify Solera if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Solera may continue to engage the IRO.

2. If Solera engages a new IRO during the term of the IA, that IRO must also meet the requirements of this Appendix. If a new IRO is engaged, Solera shall submit the information identified in Section V.A.4 of the IA to OIG within 30 days of engagement of the IRO. Within 30 days after OIG receives this information or any additional information submitted by Solera at the request of OIG, whichever is later, OIG will notify Solera if the IRO is unacceptable. Absent notification from OIG that the IRO is unacceptable, Solera may continue to engage the IRO.

B. IRO Qualifications

The IRO shall:

1. assign individuals to conduct the Quarterly Claims Review who have expertise in applicable Medicare and state Medicaid program requirements, state Board of Pharmacy requirements applicable to the pharmacy claims being reviewed, prior authorization requirements, and the requirements for collecting or waiving cost-sharing amounts for pharmacy claims;

2. assign individuals to design and select the Quarterly Claims Review sample who are knowledgeable about the appropriate statistical sampling techniques; and

3. have sufficient staff and resources to conduct the reviews required by the IA on a timely basis.
C. IRO Responsibilities

The IRO shall:

1. perform each Quarterly Claims Review in accordance with the specific requirements of the IA;

2. follow all applicable Medicare and state Medicaid program rules and reimbursement guidelines and applicable state Board of Pharmacy requirements in making assessments in the Claims Review;

3. request clarification from the appropriate authority (e.g., Medicare contractor), if in doubt of the application of a particular Medicare or state Medicaid program policy or regulation or state Board of Pharmacy policy or regulation;

4. respond to all OIG inquires in a prompt, objective, and factual manner; and

5. prepare timely, clear, well-written reports that include all the information required by Appendix B to the IA.

D. Solera Responsibilities

Solera shall ensure that the IRO has access to all records and personnel necessary to complete the reviews listed in Section III.E of this IA and that all records furnished to the IRO are accurate and complete.

E. IRO Independence and Objectivity

The IRO must perform the Quarterly Claims Review in a professionally independent and objective fashion, as defined in the most recent Government Auditing Standards issued by the U.S. Government Accountability Office.

F. IRO Removal/Termination

1. Solera and IRO. If Solera terminates its IRO or if the IRO withdraws from the engagement during the term of the IA, Solera must submit a notice explaining (a) its reasons for termination of the IRO or (b) the IRO’s reasons for its withdrawal to OIG, no later than 30 days after termination or withdrawal. Solera must engage a new IRO in accordance with Paragraph A of this Appendix and within 60 days of termination or withdrawal of the IRO.
2. **OIG Removal of IRO.** In the event OIG has reason to believe the IRO does not possess the qualifications described in Paragraph B, is not independent and objective as set forth in Paragraph E, or has failed to carry out its responsibilities as described in Paragraph C, OIG shall notify Solera in writing regarding OIG’s basis for determining that the IRO has not met the requirements of this Appendix. Solera shall have 30 days from the date of OIG’s written notice to provide information regarding the IRO’s qualifications, independence or performance of its responsibilities in order to resolve the concerns identified by OIG. If, following OIG’s review of any information provided by Solera regarding the IRO, OIG determines that the IRO has not met the requirements of this Appendix, OIG shall notify Solera in writing that Solera shall be required to engage a new IRO in accordance with Paragraph A of this Appendix. Solera must engage a new IRO within 60 days of its receipt of OIG’s written notice. The final determination as to whether or not to require Solera to engage a new IRO shall be made at the sole discretion of OIG.
APPENDIX B

QUARTERLY CLAIMS REVIEW

A. Quarterly Claims Review. The IRO shall conduct a review of Solera’s claims submitted to and reimbursed by the Medicare and Medicaid programs, to determine whether: (1) the prescription drugs furnished by Solera were dispensed according to a valid prescription, (2) Solera maintained appropriate documentation of a valid prescription for each drug dispensed (including any refills of such prescription), and (3) the claims were correctly submitted and reimbursed, for each three-month period during the term of this IA (Quarterly Claims Review) and prepare a report for each Quarterly Claims Review performed. The first three-month period shall begin 30 days following the Effective Date of this IA.

1. Definitions. For the purposes of this Appendix B, the following definitions shall be used:

a. Overpayment: The amount of money Solera has received in excess of the amount due and payable under Medicare or any state Medicaid program requirements, as determined by the IRO in connection with the Claims Review performed under this Appendix B.

b. Paid Claim: A prescription drug claim submitted by Solera and for which Solera has received reimbursement from the Medicare program or a state Medicaid program.

c. Population: The Population shall be defined as all Paid Claims during the three-month period covered by the Quarterly Claims Review. In OIG’s discretion, OIG may limit the Population to Paid Claims that required prior authorization during the three-month period covered by the Quarterly Claims Review.

2. Quarterly Claims Sample.

a. Within 15 days following the end of each three-month period during the term of the IA, the IRO shall randomly select a sample of 30 total Paid Claims submitted by or on behalf of Solera during the preceding three-month period (Quarterly Claims Sample). The sample must be selected through the use of OIG’s Office of Audit Services’ Statistical Sampling Software, also known as RAT-STATS, which is currently available at https://oig.hhs.gov/compliance/rat-stats/index.asp.

Solera Specialty Pharmacy and Nicholas Saraniti IA Appendix B
b. Solera shall provide the IRO with a list of all Solera’s Paid Claims for the three-month period covered by the Quarterly Claims Sample. The IRO should number each Paid Claim in the Population sequentially prior to generating the random numbers used to select the Quarterly Claims Sample. The IRO should generate 30 random numbers from the Population using RAT-STATS and then use the random numbers to identify the 30 Paid Claims in the Population that will be subject to review by the IRO.

c. The randomly selected 30 Paid Claims shall be reviewed by the IRO based on the supporting documentation available at Solera or under Solera’s control, applicable Medicare and state Medicaid program requirements, and applicable state Board of Pharmacy requirements to determine whether: (1) each prescription drug furnished by Solera was dispensed according to a valid prescription, (2) Solera maintained appropriate documentation of a valid prescription for each drug dispensed (including any prescription refills), (3) any prior authorization required by the payor was obtained in accordance with the payor’s requirements (e.g., the documentation contains a statement of medical necessity; the documentation accurately reflects the name, NPI, and contact information for the prescriber; and the documentation was signed by the prescriber), (4) all cost-sharing amounts were collected or waived in accordance with applicable payor requirements, and (5) the claim was correctly submitted and reimbursed.

d. If OIG elects to limit any Quarterly Claims Review to Paid Claims that required prior authorization during the covered three-month period (as described in Section A.1.c), OIG shall notify Solera no later than 10 days prior to the end of the covered three-month period. Solera shall provide the IRO with a list of all of Solera’s Paid Claims for the three-month period covered by the Quarterly Claims Sample and indicate which claims required prior authorization. The IRO shall proceed with the Quarterly Claims Review for these Paid Claims as described in Section A.2.a, A.2.b, and A.2.c above.

e. The IRO shall prepare a written report of its findings from the Quarterly Claims Sample, as described in Section C below (Quarterly Claims Review Report). The Quarterly Claims Review Report shall be submitted to the OIG within 60 days following the end of the three-month period covered by each Quarterly Claims Review.
3. **Repayment of Identified Overpayments.** Solera shall repay within 60 days any Overpayments identified by the IRO in the Quarterly Claims Sample, in accordance with the requirements of 42 U.S.C. § 1320a-7k(d) and any applicable regulations and Centers for Medicare and Medicaid Services (CMS) guidance (the “CMS overpayment rule”). If Solera determines that the CMS overpayment rule requires that an extrapolated Overpayment be repaid, Solera shall repay that amount at the mean point estimate as calculated by the IRO. Solera shall make available to OIG all documentation that reflects the refund of the Overpayment(s) to the payor. OIG, in its sole discretion, may refer the findings of the Quarterly Claims Review Sample (and any related work papers) received from Solera to the appropriate Medicare or state Medicaid program contractor for appropriate follow up by that payor.


1. **Claims Review Methodology.**

   a. **Claims Review Population.** A description of the Population subject to the Quarterly Claims Review.

   b. **Source of Data.** A description of (1) the process used to identify claims in the Population, and (2) the specific documentation relied upon by the IRO when performing the Quarterly Claims Review (e.g., electronic or hard copy prescriptions, physician orders, certificates of medical necessity, requisition forms, local medical review policies (including title and policy number), state pharmacy laws or regulations regarding the dispensing and handling of prescription drugs, CMS program memoranda (including title and issuance number), Medicare contractor or state Medicaid program manuals or bulletins (including issue and date), and other policies, regulations, or directives).

   c. **Review Protocol.** A narrative description of how the Quarterly Claims Review was conducted and what was evaluated.

   d. **Supplemental Materials.** The IRO shall request all documentation and materials required for its review of the Paid Claims in each Quarterly Claims Sample and Solera shall furnish such documentation and materials to the IRO, prior to the IRO initiating its review of the Quarterly Claims Sample. If the IRO accepts any supplemental documentation or materials from Solera after the IRO
has completed its initial review of the Quarterly Claims Sample (Supplemental Materials), the IRO shall identify in the Quarterly Claims Review Report the Supplemental Materials, the date the Supplemental Materials were accepted, and the relative weight the IRO gave to the Supplemental Materials in its review. In addition, the IRO shall include a narrative in the Quarterly Claims Review Report describing the process by which the Supplemental Materials were accepted and the IRO’s reasons for accepting the Supplemental Materials.

2. Statutory Sampling Documentation. A copy of the printout of the random numbers generated by the “Random Numbers” function of RAT-STATS used by the IRO to select the Quarterly Claims Sample.


a. Narrative Results.

i. For the first Quarterly Claims Review Report only, a description of (a) Solera’s claim submission system(s), including the identification, by position description, of the personnel involved in claim submission, and (b) a description of controls in place to ensure that all prescription drugs billed to Medicare or a state Medicaid program are dispensed and billed in accordance with a valid prescription, that documentation of the prescription (including any refills) is maintained, and that the claims are correctly submitted and reimbursed including compliance with any prior authorization requirements and requirements relating to the collection or appropriate waiver of any cost-sharing amounts. Subsequent Quarterly Claims Review Reports should describe any significant changes to items (a) and (b) or, if no significant changes were made, state that the systems and controls remain the same as described in the prior Quarterly Claims Review Report.

ii. A narrative explanation of the results of the Quarterly Claims Sample, including reasons for errors, patterns noted, etc.

b. Quantitative Results.

i. Total number and percentage of instances in which the IRO determined that the Paid Claims submitted by Solera were not
supported by valid prescriptions or did not otherwise meet all applicable Medicare and state Medicaid program requirements (including but not limited to any prior authorization requirements) and in which such errors resulted in an Overpayment to Solera.

ii. Total number and percentage of instances in which the IRO determined that Solera failed to collect or inappropriately waived any cost-sharing amount.

iii. Total number and percentage of instances in which the IRO determined prior authorization was not obtained in accordance with the payor’s requirements (e.g., the documentation did not contain a statement of medical necessity; the documentation did not accurately reflect the name, NPI, and contact information for the prescriber; or the documentation was not signed by the prescriber).

iv. Total dollar amount of all Overpayments in the Quarterly Claims Review Sample.

v. Total dollar amount of Paid Claims included in the Quarterly Claims Review Sample.

vi. Error Rate in the Quarterly Claims Review Sample. The Error Rate shall be calculated by dividing the Overpayment in the Quarterly Claims Review Sample by the total dollar amount associated with the Paid Claims in the Quarterly Claims Review Sample.

vii. An estimate of the actual Overpayment in the Population at the mean point estimate.

viii. A spreadsheet of the Quarterly Claims Sample results that includes the following information for each Paid Claim: Federal health care program billed, beneficiary health insurance claim number, prescription fill date, National Drug Code (NDC) submitted, NDC reimbursed, quantity prescribed, quantity dispensed, quantity reimbursed, amount reimbursed by payor, correct NDC (as determined by the IRO), correct amount reimbursed (as determined by the IRO), and any dollar difference between amount reimbursed by
payor and the correct amount reimbursed (as determined by the IRO).

c. Recommendations. The IRO’s report shall include any recommendations for improvements to Solera’s claims submission system or to Solera’s controls for ensuring that all prescription drugs billed to Medicare or a state Medicaid program are dispensed and billed in accordance with a valid prescription and otherwise meet all Medicare and applicable state Medicaid program requirements, including any prior authorization requirements and requirements relating to the collection of cost-sharing amounts, that documentation of the prescription (including any refills) is maintained, and that the claims are correctly submitted and reimbursed, based on the findings of the Quarterly Claims Review.

d. Credentials. The names and credentials of the individuals who: (1) designed the review methodology utilized for the Quarterly Claims Review and (2) performed the Quarterly Claims Review.

C. Other Requirements. The following requirements apply to any Quarterly Claims Review performed pursuant to this Appendix B.

1. Paid Claims without Supporting Documentation. Any Paid Claim for which Solera cannot produce documentation shall be considered an error and the total reimbursement received by Solera for such Paid Claim shall be deemed an Overpayment. Replacement sampling for Paid Claims with missing documentation is not permitted.

2. Use of First Samples Drawn. For the purposes of all samples discussed in this Appendix, the Paid Claims selected in each first sample shall be used (i.e., it is not permissible to generate more than one list of random samples and then select one for use with the sample).